BioStem Technologies, Inc. (OTCMKTS:BSEM - Get Free Report) saw a large drop in short interest in November. As of November 30th, there was short interest totalling 117,700 shares, a drop of 21.2% from the November 15th total of 149,400 shares. Based on an average daily volume of 197,300 shares, the short-interest ratio is currently 0.6 days.
BioStem Technologies Stock Performance
Shares of BioStem Technologies stock traded up 0.97 during trading hours on Friday, reaching 17.21. 60,658 shares of the company were exchanged, compared to its average volume of 38,093. The stock's fifty day moving average is 15.10 and its 200 day moving average is 11.44. BioStem Technologies has a 1 year low of 4.28 and a 1 year high of 28.26. The firm has a market cap of $286.07 million, a PE ratio of 23.89 and a beta of -0.62.
BioStem Technologies (OTCMKTS:BSEM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported 0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of 0.31 by 0.01. The business had revenue of 82.56 million for the quarter, compared to analysts' expectations of 78.22 million. Research analysts expect that BioStem Technologies will post 1.41 earnings per share for the current year.
BioStem Technologies Company Profile
(
Get Free Report)
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
Featured Articles
Before you consider BioStem Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioStem Technologies wasn't on the list.
While BioStem Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
